Retatrutide vs semaglutide: how do they compare?

Semaglutide is a single-pathway (GLP-1) medication available today under physician supervision, with well-established dosing and safety monitoring. Retatrutide is an investigational triple-pathway drug (GLP-1, GIP, and glucagon) that is not FDA-approved and not available by prescription. The most important difference for anyone deciding what to do now: semaglutide is a real, monitored option, while retatrutide is still in trials.

What each one targets

Semaglutide works through the GLP-1 pathway to reduce appetite and slow stomach emptying. Retatrutide is designed to hit three pathways at once. Trial data for triple agonists is promising, but promising trial results are not the same as an approved, quality-controlled medication you can safely obtain.

The practical takeaway

If your goal is to start now, semaglutide is a proven, physician-supervised path with medication from licensed U.S. pharmacies. Keep an eye on retatrutide for the future, but don't source it from gray-market sellers in the meantime.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.